Can Fite Biofarma Ltd (CANF)

2.20
AMEX : Health Care
Prev Close 2.12
Day Low/High 2.09 / 2.20
52 Wk Low/High 1.85 / 3.59
Avg Volume 68.10K
Exchange AMEX
Shares Outstanding 13.85M
Market Cap 29.37M
EPS -0.40
P/E Ratio 3.48
Div & Yield N.A. (N.A)

Latest News

Can-Fite Advances Towards A Pivotal Phase III Clinical Trial In Psoriasis With Piclidenoson (CF101) Following Reaching Agreement With EMA

Can-Fite Advances Towards A Pivotal Phase III Clinical Trial In Psoriasis With Piclidenoson (CF101) Following Reaching Agreement With EMA

- Phase III clinical study designed to establish Piclidenoson is superior to placebo as primary endpoint and non-inferior to Otezla® at week 32 as secondary endpoint

Can-Fite Signs Distribution Deal For Liver Cancer Drug CF102 In South Korea

Can-Fite Signs Distribution Deal For Liver Cancer Drug CF102 In South Korea

- Deal provides for up to $3,000,000 in upfront and milestone payments & a percentage rate of royalty payments in the low twenties

Can-Fite Submits Protocol For Phase II Trial Of CF102 In The Treatment Of NAFLD/NASH

Can-Fite Submits Protocol For Phase II Trial Of CF102 In The Treatment Of NAFLD/NASH

- Leading Israeli medical institutions Hadassah and Rabin Medical Centers to be included in the trial

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKD, CCE, CFBK, FIT Downgrades: FWRD, SIG, VIA Initiations: CANF Read on to get TheStreet Quant Ratings' detailed report:

Can-Fite Reports New Data On CF102's Liver Protective & Regenerative Properties Published In Scientific Journal

Can-Fite Reports New Data On CF102's Liver Protective & Regenerative Properties Published In Scientific Journal

- Article published in Molecular Medicine Reports

Can-Fite Receives Notice Of Allowance For Psoriasis Patent In Europe Ahead Of Phase III Trial

Can-Fite Receives Notice Of Allowance For Psoriasis Patent In Europe Ahead Of Phase III Trial

- 2.4 million Europeans living with moderate-to-severe psoriasis

Can-Fite Completes Phase II Study Design For CF102 In The Treatment Of NASH/NAFLD

Can-Fite Completes Phase II Study Design For CF102 In The Treatment Of NASH/NAFLD

- NASH/NAFLD are the leading cause of liver disease in Western countries

Can-Fite Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects

Can-Fite Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects

- Similar to biologics, Piclidenoson (CF101) inhibits inflammatory proteins IL-17 and IL-23

Can-Fite Submits Psoriasis Phase III Protocol And Registration Plan To EMA For Piclidenoson (CF101)

Can-Fite Submits Psoriasis Phase III Protocol And Registration Plan To EMA For Piclidenoson (CF101)

- Phase III protocol is a head-to-head trial comparing Piclidenoson to Otezla®

Can-Fite To Exhibit At Bio International Convention In San Francisco On June 6-9, 2016

Can-Fite To Exhibit At Bio International Convention In San Francisco On June 6-9, 2016

Company also to participate as a member of the Israeli Biotech Delegation at Perspectives on Biotech Investing on June 6

Can-Fite Reaches Agreement With EMA On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis

Can-Fite Reaches Agreement With EMA On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis

- EMA suggests development of Piclidenoson as a first line therapy and alternative for methotrexate, the standard of care for rheumatoid arthritis

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

Can-Fite BioPharma (CANF) stock is gaining on Monday afternoon as the company announced pre-clinical data for CF602, which demonstrated statistically significant full recovery from erectile dysfunction after a single dose.

Can-Fite Announces New Pre-Clinical Data For CF602 Demonstrating Statistically Significant Full Recovery From Erectile Dysfunction After A Single Dose

Can-Fite Announces New Pre-Clinical Data For CF602 Demonstrating Statistically Significant Full Recovery From Erectile Dysfunction After A Single Dose

CF602 may provide benefits for patients who cannot take or do not respond to erectile dysfunction drugs currently on the market

Can-Fite CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016

Can-Fite CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016

Dr. Fishman is one of a select number of global Key Opinion Leaders on drugs targeting A3AR receptors

U.S. Patent & Trademark Office Issues Notice Of Allowance For Can-Fite's Sexual Dysfunction Drug CF602

U.S. Patent & Trademark Office Issues Notice Of Allowance For Can-Fite's Sexual Dysfunction Drug CF602

- Composition of matter patent protects use of an A3AR modulator for the treatment of any indication

Can-Fite Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications

Can-Fite Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications

- Phase III trials in rheumatoid arthritis and psoriasis expected to commence in 2016